# Continuous wound infiltration versus placebo following elective minimally invasive colorectal surgery (CIMICS): study protocol for a randomised controlled trial

**Authors:** Sofie Glazemakers, Stijn H.J. Ketelaers, Harm J. Scholten, Robert-Jan Schipper, Michaël I. Meesters, Jacobus W.A. Burger, Johanne G. Bloemen

PMC · DOI: 10.1371/journal.pone.0340859 · PLOS One · 2026-01-21

## TL;DR

This trial tests if continuous wound infiltration with bupivacaine improves recovery after minimally invasive colorectal surgery compared to placebo.

## Contribution

This is the first randomized controlled trial to evaluate continuous wound infiltration in ERAS-adherent minimally invasive colorectal surgery.

## Key findings

- The trial will assess the impact of CWI on postoperative recovery using the QoR-15 score.
- Results may influence evidence-based guidelines for multimodal analgesia in colorectal surgery.
- The study will provide data on opioid consumption and hospital stay duration.

## Abstract

Enhanced Recovery After Surgery (ERAS) programs emphasize multimodal analgesia to minimize opioid use and improve patient outcomes. Continuous wound infiltration (CWI) with local analgesic is a promising adjunct to multimodal analgesia. However, its benefits in minimally invasive procedures and ERAS-adherent care remain unknown. This trial investigates whether the addition of CWI to standard ERAS care improves postoperative recovery following minimally invasive colorectal surgery.

In this single-centre, blinded, randomised controlled trial, 192 eligible patients are randomised to receive either a CWI system with bupivacaine 0.125% (the interventional arm), or a placebo CWI with physiological saline (the control arm). All patients receive standardized ERAS perioperative care with multimodal analgesia. The primary outcome is the Quality of Recovery-15 score (QoR-15NL) on postoperative day 2. Secondary outcomes include QoR-15NL and pain scores (postoperative days 1–5), opioid consumption, length of hospital stay, key functional recovery milestones, and 90-day postoperative complications.

This will be the first randomised controlled trial evaluating the effect of CWI within minimally invasive and ERAS-adherent colorectal surgery. The trial findings may improve evidence-based perioperative care guidelines and enhance postoperative multimodal analgesia.

## Linked entities

- **Chemicals:** bupivacaine (PubChem CID 2474)

## Full-text entities

- **Diseases:** postoperative (MESH:D019106), pain (MESH:D010146)
- **Chemicals:** bupivacaine (MESH:D002045)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12822994/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12822994/full.md

## References

30 references — full list in the complete paper: https://tomesphere.com/paper/PMC12822994/full.md

---
Source: https://tomesphere.com/paper/PMC12822994